Brookline downgraded Hepion Pharmaceuticals to Hold from Buy after the company announced that its board approved a strategic restructuring plan and initiated a process to explore a range of strategic and financing alternatives as well as announcing Dr. Robert Foster resigned as CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HEPA:
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Hepion Pharmaceuticals announces reduction in liver stiffness with rencofilstat
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
